gfp,
I'm in KZIA in a big way. Got in around $4, so doing fine. Potential to be a 20X-bagger. Virtually unknown on The Street. A miniscule 7.5 million shares outstanding. A possible presentation at SNO (Society of Neuro-Oncology) in Novemeber. All the caveats apply including it being an Australian biotech.(ugh) My cancer docs like it. The trials are being run at Dana-Farber and MSK and St. Judes. Drug is a small molecule developed by Genentech. Recently got orphan drug designation. Also, fast track. If Phase II data is good, KZIA will look to get accelerated approval with priority review.
Bladerunner
News 
Market Data 
Discover 
